Zhe Jiang Dayang Biotech Group Co., Ltd. (SHE:003017)
China · Delayed Price · Currency is CNY 21.87
-0.65 (-2.89%)
Sep 11, 2026, 1:50 PM CST
SHE:003017 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 2,243 | 2,479 | 1,517 | 1,948 | 1,646 | 2,508 | |
Market Cap Growth | -25.24% | 63.34% | -22.09% | 18.30% | -34.36% | -19.23% |
Enterprise Value | 2,302 | 2,387 | 1,479 | 1,827 | 1,516 | 2,198 |
Last Close Price | 22.52 | 24.60 | 15.02 | 19.04 | 15.21 | 22.52 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 22.68 | 24.82 | 23.80 | 38.95 | 20.39 | 35.82 |
PS Ratio | 2.03 | 2.37 | 1.67 | 2.12 | 1.56 | 3.20 |
PB Ratio | 1.91 | 2.18 | 1.44 | 1.93 | 1.67 | 2.53 |
P/TBV Ratio | 2.09 | 2.37 | 1.58 | 2.13 | 1.85 | 2.69 |
P/FCF Ratio | - | 29.61 | 552.98 | 24.72 | - | - |
P/OCF Ratio | 22.80 | 15.48 | 22.92 | 10.68 | 17.92 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.08 | 2.28 | 1.63 | 1.99 | 1.43 | 2.81 |
EV/EBITDA Ratio | 12.56 | 13.05 | 10.46 | 14.63 | 13.81 | 19.88 |
EV/EBIT Ratio | 21.52 | 21.40 | 20.12 | 32.60 | 30.07 | 33.15 |
EV/FCF Ratio | - | 28.51 | 538.83 | 23.19 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.39 | 0.32 | 0.35 | 0.25 | 0.29 | 0.18 |
Debt / EBITDA Ratio | 2.47 | 2.00 | 2.59 | 1.99 | 2.55 | 1.61 |
Debt / FCF Ratio | - | 4.38 | 133.95 | 3.18 | - | - |
Net Debt / Equity Ratio | 0.05 | -0.08 | -0.03 | -0.13 | -0.15 | -0.23 |
Net Debt / EBITDA Ratio | 0.30 | -0.51 | -0.19 | -1.06 | -1.32 | -2.10 |
Net Debt / FCF Ratio | -1.34 | -1.11 | -9.79 | -1.67 | 11.40 | 1.80 |
Asset Turnover | 0.61 | 0.60 | 0.57 | 0.60 | 0.73 | 0.60 |
Inventory Turnover | 6.71 | 7.12 | 5.43 | 5.43 | 6.33 | 5.47 |
Quick Ratio | 0.76 | 1.01 | 0.93 | 1.15 | 1.20 | 1.78 |
Current Ratio | 1.00 | 1.22 | 1.22 | 1.54 | 1.52 | 2.34 |
Return on Equity (ROE) | 9.44% | 9.14% | 6.18% | 5.02% | 8.17% | 7.18% |
Return on Assets (ROA) | 3.71% | 4.02% | 2.87% | 2.29% | 2.19% | 3.18% |
Return on Invested Capital (ROIC) | 8.41% | 10.09% | 6.87% | 6.53% | 6.31% | 9.19% |
Return on Capital Employed (ROCE) | 8.60% | 9.40% | 6.80% | 5.00% | 4.90% | 6.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.76% | 4.03% | 4.20% | 2.57% | 4.90% | 2.79% |
FCF Yield | -1.83% | 3.38% | 0.18% | 4.05% | -0.78% | -5.13% |
Dividend Yield | 2.18% | 2.03% | 1.67% | 3.22% | 0.78% | 1.59% |
Payout Ratio | 50.04% | 54.73% | 67.00% | 85.20% | 48.38% | 54.72% |
Buyback Yield / Dilution | -19.25% | -0.30% | -1.63% | 1.00% | 2.93% | -26.42% |
Total Shareholder Return | -17.08% | 1.73% | 0.04% | 4.22% | 3.71% | -24.83% |